DUBLIN – Translate Bio Inc. is the first beneficiary to gain from Sanofi SA’s massive $11.7 billion addition to its balance sheet, following its recent disposal of its holdings in long-time partner Regeneron Pharmaceuticals Inc. Lexington, Mass.-based Translate Bio is getting $300 million up front, another $125 million in equity investment and up to $1.9 billion in milestones under a major expansion of an existing agreement with Paris-based Sanofi to develop mRNA-based vaccines for infectious disease.

Invitae Corp. (NYSE:NVTA) saw its stock flying high June 22 on the news of its agreement to buy Archerdx Inc., with an eye toward enhancing cancer genetics and precision oncology. Investors appear to approve of the deal, with the company’s stock closing at $27.05, up $8.34 or 44.58%.

San Diego-based Illumina Inc. is synonymous with next-generation sequencing (NGS) equipment. But when it comes to dealmaking, the genomics giant is focused largely on software to make its results more useful, accessible and affordable. It has acquired cloud-based software startup Bluebee Holding BV in its latest move on this front.

PERTH, Australia – Sydney-based Speedx Pty. Ltd. has signed a global distribution deal with Roche Holding AG, through which the latter will sell Speedx’s Resistanceplus MG and Resistanceplus GC molecular tests for detecting antimicrobial resistance to Mycoplasma genitalium (Mgen) and gonorrhea, respectively.

Lausanne, Switzerland-based Debiotech SA and Neokidney BV, of Amsterdam, have created Nextkidney SA to lead the development and commercialization of Neokidney, a lightweight, plug-and-play, home hemodialysis device.

HONG KONG – Korea’s Celltrion Inc. aims to wrap up its first major M&A deal with Japan’s Takeda Pharmaceutical Inc. by the end of 2020, pending approvals.

PARIS – Agfa-Gevaert Group NV, of Mortsel, Belgium, has sold parts of its health care information technology (IT) business to Italy’s Dedalus Holding SpA for $1.1 billion. The divested interests include health care information solutions activities and integrated care activities in Germany, Austria, Switzerland, France and Brazil, as well as certain IT imaging activities in these territories. It represents about half of Agfa Healthcare’s business.

Neurocrine Biosciences Inc.’s chief business development and strategy officer, Kyle Gano, said “there was really no playbook” for the deal in which his firm is paying Takeda Pharmaceutical Co. Ltd. $120 million up front for an exclusive license to seven programs, including three clinical-stage assets targeting the notoriously difficult indications of schizophrenia and treatment-resistant depression (TRD), as well as depression-related anhedonia.